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INTRODUCTION 
Allergic rhinitis (AR), also known as pollenosis or hay 
fever, is an IgE mediated hypersensitivity disease of the 
mucous membranes of the nasal airways [1]. AR has a 
relevant impact on society because of its high preva-
lence, association with an impaired quality of life and 
the presence of comorbidities such as atopy and asth-
ma [2].  
It affects a large percentage of paediatric patients and 
causes significant number of school days missed per 
year. Impairment of work in adults also occurs affecting 
the finances of patients indirectly through lost work-
days and directly through healthcare cost spent for the 
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disease [3]. 
Seasonal allergic rhinitis (SAR) is found in = 10% of the 
general population and perennial allergic rhinitis (PAR) 
in 10-20% of the population [1]. 
In both SAR & PAR, the underlying process is an allergic 
response to airborne allergens of different nature. The 
disorder is associated with the epithelial accumulation 
of effector cells, such as mast cells and basophils, and 
inflammation in the nasal mucosa. Immunological acti-
vation of these effector cells induces the secretion of 
both newly generated (leukotrienes, prostaglandins 
and kinins) and pre formed (histamine and tryptase) 
pro inflammatory mediators [4]. Quantitatively, hista-
mine is the most abundant preformed mediator in the 
early phase response and its implication in many of the 
symptoms of the disease has been clearly demonstrat-
ed. (Sneezing, itching, watery eyes and rhinorrhoea) 
Platelet activating factor (PAF) is an important media-
tor of AR causes vasodilation and an increase in vascu-
lar permeability that may contribute to the appearance 
of rhinorrhoea and nasal congestion [5]. 
ABSTRACT 
Aim:  To compare the therapeutic efficacy and safety of Rupatadine and mometasone with Levocetirizine which is 
most commonly used drug. To study the effects of levocetirizine, Rupatadine and mometasone on absolute eosino-
phil count and IgE levels. Methodology: The participants were randomly divided into 3 groups of 25 patients each 
and treated as follows: Group I: were treated with Levocetirizine 5mg OD for 14 days, Group II: were treated with 
Rupatadine 10mg OD for 14 days, Group III: were treated with Mometasone two sprays (50mcg of mometasone in 
each spray) in each nostril once daily (total daily dose of 200mcg) for 14 days. The patients were asked to report at 
the hospital after 14 day and they were followed up with regard to clinical improvement of symptoms and signs and 
any adverse effects as reported by the patient. Rhinoscopy finding, X- ray of para nasal sinus, improvement in symp-
toms (sneezing, Itching, nasal discharge, nasal blockage and anosmia) Absolute eosinophils count, Serum IgE levels 
and adverse reports were studied and investigation were compared before and after treatment.  Result: Rhinoscope 
finding showed treatment with mometasone became normal but X- Ray of para nasal sinus results showed levocetir-
zine showed higher rate of improvement. In improvement of symptoms sneezing, itching and nasal discharge was 
high mometasone.  In all groups post treatment there was no changes in Ig E and Absolute Eosinophil’s count. ADR 
reported with mometaxone. Conclusion: The three drugs, levocetirizine, rupatadine and mometasone were found to 
have similar levels of efficacy in controlling the symptoms of the allergic rhinitis. The physical signs improved better 
with mometasone than the other 2 drugs. The 3 drugs levocetirizine, rupatadine and mometasone had no significant 
effect on the absolute eosinophil count and the serum IgE levels. Adverse effects were found to be more with levoce-
tirizine than the other two drugs. Considering this factor and also the fact that long term use of corticosteroids like 
mometasone is undesirable, rupatadine appears to be a better choice in the treatment of allergic rhinitis. 
Keywords: Levocetirizine; Rupatadine; Mometasone; Allergic Rhinitis; Safety; Efficacy Adverse Reactions. 
 







Moreover PAF and histamine are known t complement 
each other in vivo, histamine is a mediator of early re-
sponse, being released from preformed reservoirs in 
mast cells, whereas PAF, a mediator of late  response, 
is mainly synthesized denovo [6,7]. Furthermore, each 
of these mediators is able to promote the release of 
the other in some tissues and numerous target cells [8]. 
From the available experimental evidence it could be 
reasonable to infer that the blockade of both histamine 
and PAF receptors could be of superior clinical efficacy 
than the blockade of any one of these receptor types in 
the treatment of AR.  Levocetirizine is conventionally 
used drug for allergic rhinitis which has good therapeu-
tic efficacy but it has got more adverse drug reactions 
and all effects are short lived, so search for better drug 
continues, rupatadine and mometasone are such drugs 
with better therapeutic efficacy and safety profile.    
This study compares the therapeutic efficacy and safety 
of rupatadine and mometasone with levocetirizine 
which is most commonly used drug in government hos-
pitals for the treatment of allergic rhinitis. 
Aim:  
To compare the therapeutic efficacy and safety of Ru-
patadine and mometasone with Levocetirizine which is 
most commonly used drug. 
To study the effects of levocetirizine, Rupatadine and 
mometasone on absolute eosinophil count and IgE lev-
els. 
MATERIALS AND METHODS  
Study design: Open label and parallel group compara-
tive clinical study 
Ethics approval:  The study was approved by institu-
tional ethics committee and informed consent was ob-
tained from the participants. 
Study location: The cases for this study were taken 
from the allergy clinic of government 
ENT, Hospital, Koti, Hyderabad 
Sample size: A total of 75 patients, showing signs and 
symptoms suggestive of allergic rhinitis were taken.  
Inclusion criteria: Patients in the age group of 15 -45 
years of both sexes were included in the study.  Clinical 
Features: Patients showing the typical features of aller-
gic rhinitis such as sneezing, watery nasal discharge, 
itching in the nose / throat and nasal blockade were 
included. The duration of these symptoms and signs 
had to be of at least 1 month or more to rule out com-
mon cold or other minor infections of the 
upper respiratory tract. 
Exclusion criteria: Infections of the respiratory tract as 
indicated by purulent discharge, foul 
smelling discharge or fever, patients who had used anti
-histamines in the past 48 hours or topical steroids 
in the past 2 weeks or systemic steroids in the past 4 
weeks. The above drugs alter the clinical picture and 
also interfere with the skin test for allergy. Any previ-
ous history of hypersensitivity to anti-histamines or 
corticosteroids. Evidence of major systemic disease, 
pregnant / lactating women, patients undergoing de-
sensitization (Immunotherapy) and firstly it shows any 
infection in the sinuses as generalized haziness in the 
sinuses. Such cases were excluded from this study as 
per the exclusion criteria were excluded.  
Grouping and dose [9-12]:  
The participants were randomly divided into 3 groups 
of 25 patients each and treated as follows  
Group I: were treated with Levocetirizine 5mg OD for 
14 days 
Group II: were treated with Rupatadine 10mg OD for 14 
days  
Group III: were treated with Mometasone two sprays 
(50mcg of mometasone in each spray) in each nostril 
once daily (total daily dose of 200mcg) for 14 days 
Methodology: 
Patients in group-I received tablets of levocetirizine 
5mg OD orally for 14 days. Patients in group-II received 
tablets of Rupatadine 10mg OD orally for 14 days. Pa-
tients in group-III received one container of mometa-
sone nasal spray (10gm-100metered doses of 50mcg) 
and instructed to take two sprays (50mcg of 
mometasone in each spray) in each nostril once daily 
(total daily dose of 200mcg) for 14 days.  
The patients were asked to report at the hospital after 
7 days and they were followed up with regard to clini-
cal improvement of symptoms and signs and any ad-
verse effects as reported by the patient. After comple-
tion of the total duration of 14 days of treatment the 
patients again reported at the hospital. They 
were followed up with regard to clinical improvement, 
any adverse effects reported and also by repeated all 
the investigations done before starting of the treat-
ment. 
The patients in all groups were instructed not to take 
any medicine other than the tablets provided to them 
during the study period. They were also told to stop the 
medication if they noticed any major undesirable 
effects and to inform the same to the doctors at the 
allergy clinic. 
Parameters: Rhinoscopy finding, X- ray of para nasal 
sinus, improvement in symptoms (sneezing, Itching, 
nasal discharge, nasal blockage and anosmia) Absolute 
eosinophils count [9], Serum IgE levels [9] and adverse 
reports were studied. 
Absolute eosinophil count: This test was done pre and 
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post treatment to observe any effect of the given drug 
on the absolute eosinophil count. 
Measurement of Serum IgE levels: Levels of IgE in the 
serum is a strong point in favor of 
diagnosing allergic Rhinitis. After taking the blood sam-
ples from the patients the serum was separated by 
Centrifugation and stored at -20" C until the ELISA test 
was performed. The ELISA kit (for measuring IgE levels) 
used in this study was produced by Omega Diagnostics 
Limited, United Kingdom, and was purchased from Hy-
derabad [13]. Calculation of IgE values: This was done 
by the computer attached to the automatic analyzer. It 
gives the IgE concentration in IU/ml 
RESULTS 
Group Rhinoscopy X- Ray of para nasal sinus 
Before 
treatment 
After treatment number of pa-
tients showing improvement 
Before 
treatment 
After treatment number of patients 
showing improvement 
No Partial Normal   No Partial Normal 
Group 1 22 4 (18.8) 10 (45.5) 8(36.4) 3 0 0 3 (100) 
Group II 19 4 (21.1) 6 (31.6) 9 (47.4) 3 1 (33.3) 0 2 (66.7) 
Group III 20 3 (15) 7 (35) 10 (50) 3 1 (33.3) 0 2 (66.7) 
Improvement Group I Group II Group III Group I Group II Group III 
Sneezing Itching 
No 1 1 0 0 1 1 
Mild  (25% ) 3 1 2 0 2 0 
Moderate (50%) 6 5 2 3 3 0 
Good (75%) 5 10 10 1 3 1 
Total (100%) 10 8 11 8 3 8 
Overall (%) 70 73 80 85.4 60.4 87.5 
Nasal Discharge Nasal Blocking 
No 1 0 0 3 3 3 
Mild  (25% ) 1 2 3 1 2 4 
Moderate (50%) 3 5 2 5 3 6 
Good (75%) 9 4 5 3 5 2 
Total (100%) 9 12 13 3 3 2 
Overall (%) 76.1 78.3 80.4 53.3 54.7 44.1 
Anosmia   
No 1 0 0 
Mild  (25% ) 0 0 1 
Moderate (50%) 0 0 1 
Good (75%) 2 1 2 
Total (100%) 3 2 1 
Overall (%) 75 91.7 65 
Table 1. Rhinoscopy and x- ray of para nasal sinus findings after treatment  
Table 2. Improvement in Symptoms 
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In this study of 75 cases, all the patients (100%) with 
allergic rhinitis had sneezing, watery nasal discharge 
was present in 69 patients (92%). Itching / palate / 
throat) was reported by 34 patients (45%), nasal block-
ing by 48 patients (64%) and Anosmia by 14 patients 
(19%). 
Thus, sneezing and watery nasal discharge were the 
most common complaints. Anosmia was the least com-
mon and usually secondary to nasal blocking. When 
asked about the history of exposure to any specific 
agent, most of the patients answered in the negative. 
History of allergic disorders in family members was 
reported by 18 patients (24%). 
History taking was followed by general, systemic and 
EN.T. examination of the patient. Rhinoscopy was done 
to see the appearance of nasal mucosa, the presence of 
any nasal discharge, the position of the nasal septum, 
the condition of the turbinates and any other findings. 
Of the 75 cases in this study, 61 cases (81.33%) showed 
at least one or more signs of allergic rhinitis which in-
clude pale nasal mucosa, mucosal edema, and pres-
ence of watery discharge, mucosal congestion and hy-
pertrophy of turbinates. 
After examining the patient, investigations were done. 
X-ray of the Para nasal sinuses was taken to detect any 
sinusitis and also to see for mucosal thickening which is 
indicative of allergy involving the sinuses. Cases show-
ing mucosal thickening had a repeat x-ray to see for 
any improvement after treatment. Out of the total 
number of 75 cases, 9 cases showed mucosal thicken-
ing in the maxillary sinuses before starting treatment.  
Blood samples were taken for doing investigations like 
complete blood picture, absolute eosinophil count and 
measurement of immunoglobulin - E (IgE) levels. 49 out 
of 75 patients (65%) showed eosinophil counts above 
normal levels and 61 out of 75 patients (81%) showed 
IgE levels above normal, before starting treatment. 
The following results were obtained after 14 days of 
treatment. Symptomatic vement was similar with the 
three drugs in relation to sneezing and nasal. The over-
all reduction in sneezing was 70% with Levocetirizine, 
73% with Rupatadine, and 80% with mometasone. Na-
sal discharge reduced by 76% with Levocetirizine, 78% 
with Rupatadine, and 80% with mometasone. Itching 
was better controlled by mometasone (88%) as com-
pared to Levocetirizine (85%) and Rupatadine (60%). 
Relief of nasal blocking was more or less similar with all 
the three drugs i.e., 53% with levocetirizine 55% with 
Rupatadine and 44% with mometasone. Anosmia re-
duced by 75% with levocetirizine, 92% with Rupatadine 
and 65% with Mometasone. Physical signs of allergic 
rhinitis as seen by rhinoscopy improved better with 
Mometasone, 50% of patients showing normal appear-
ance of nasal cavity after treatment as compared to 
47% with Rupatadine and 36% with Levocetirizine. 
The effects of Levocetirizine (mean reduction-1%), Ru-
patadine (mean reduction 2%) and Mometasone (mean 
rise-2%) on serum IgE values, were not significant. Ru-
patadine produced a minor fall of around 4% in the 
mean absolute eosinophil count whereas Levocetirizine 
and Mometasone produced a fall of around 3% respec-
tively. These changes in IgE values and absolute eosino-
phil count are in agreement with the results published 
from previous studies.  
Regarding the skin test for allergy, the skin test result 
became negative in 61% of patients with Levocetirizine, 
in 73% of Patients with Rupatadine, and in 81% of pa-
tients with Mometasone. Mean % reduction of skin 
reaction were 82% with Levocetirizine, 93% with Rupa-
tadine, and 92% with Mometasone. 
X-ray of paranasal sinuses was suggestive of allergy in 3 
patients in each of the 3 groups. Out of them 2 patients 
in Rupatadine group and 2 patients in Mometasone 
group had normal X-rays after treatment while all the 3 
  Ig E values (IU/ml) Absolute Eosinophil’s count 
Group Before treatment After treatment Before treatment After treatment 
Group I 263±39 260±43 575±76 558±67 
Group II 199±31 195±32 787±98 755±94 
Group III 176±15 180±17 536±64 522±60 
Table 3. Ig E and Absolute Eosinophil’s count before and after treatment  
Group No of patient   Dryness of Drowsiness Other 
Group I 12 5 7 Nil 
Group II 5 4 1 Nil 
Group III 3 Nil Nil 
Nausea, Dyspepsia nasal burning sensation 
and irritation and 
Table 4. ADR reported  
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patients of the levocetirizine group had normal x-ray 
after treatment.  
Adverse effects were reported by patients of all the 3 
groups. Although a Significant number of patients re-
ported adverse effects; these were mild and lasted only 
a few days. Dryness of mouth/throat was reported by 4 
patients on Rupatadine and by 5 Patients on levoce-
tirizine. Drowsiness was reported by 7 patients on 
levocetirizine and only by 1 patient on rupatadine. Pa-
tients on anti-histamines reported no other adverse 
effect. Among the patients on Mometasone, nausea, 
dyspepsia and nasal burning sensation and irritation 
was reported in one patient each. All these adverse 
effects subsided by themselves with continued treat-
ment. 
A study by Rituparna Maiti etal compared the Rupata-
dine and levocetirizine on differential count and abso-
lute eosinophil count was significantly lowered by both 
drugs, but rupatadine was found to be superior. In the 
rupatadine group there was a significantly higher re-
duction in IgE level compared with the levocetirizine 
group. Incidence of adverse effects was less in the ru-
patadine group compared with the levocetirizine 
group. 
Rupatadine significantly reduced sneezing scores more 
than that of levocetirizine, which is consistent with pre-
vious study that Rupatadine reduces TNSS and Rhino-
conjunctivitis quality of life Questionnaire scores to a 
greater extent than Levocitrizine in seasonal allergic 
rhinitis patients [11]. 
Emel etal study reported that moderate to severe per-
sistent allergic rhinitis patients, adding levocetirizine or 
montelukast to mometasone furoate is more effective 
than mometasone furoate alone [11]. 
Singh etal in his study concluded as mometasone 
Fuorate nasal spray and Levocetrizine are potent drugs 
but patients taking Mometasone Fuorate nasal spray as 
medication appreciate better relief in symptoms as 
compared to Levocetrizine [12]. 
A study by Sridhar Rao [14] all the adverse effect com-
plained were expected and no new/alarming side 
effects were recorded with levocitrizine in treatment of 
allergic rhinitis and our result also supporting his study. 
CONCLUSION 
The three drugs, levocetirizine, rupatadine and momet-
asone were found to have similar levels of efficacy in 
controlling the symptoms of the allergic rhinitis. The 
physical signs improved better with mometasone than 
the other 2 drugs. The 3 drugs levocetirizine, rupata-
dine and mometasone had no significant effect on the 
absolute eosinophil count and the serum IgE levels. 
Adverse effects were found to be more with levocetiriz-
ine than the other two drugs. Considering this factor 
and also the fact that long term use of 
corticosteroids like mometasone is undesirable, rupata-
dine appears to be a better choice in the treatment of 
allergic rhinitis. 
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